High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234

N. J. Vogelzang, J. E. Herndon, A. Miller, G. Strauss, G. Clamon, F. M. Stewart, Joseph Aisner, A. Lyss, M. R. Cooper, Y. Suzuki, M. R. Green

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

Background: New agents with activity in mesothelioma are sorely needed. The Cancer and Leukemia Group B (CALGB) therefore performed a phase II study of high-dose paclitaxel in patients with malignant mesothelioma who had no prior chemotherapy.Patients and methods: Thirty-five patients accrued to this multi-institutional phase II study of paclitaxel given as a 24-hour infusion at 250 mg/m2 every three weeks plus filgrastim (G-CSF) 300 meg subcutaneously days 3-18.Results: There were three (9%) regressions of evaluable disease. The median survival was five months (95% confidence interval (95% CI): 1.9-9.6 months), the one-year survival rate was 14% and the two-year survival rate was 6%. Toxicity was tolerable with one death from pneumonia (without neutro-penia) on day 18 and a 23% rate of grade 4 granulocytopenia.Conclusions: The level of activity seen with paclitaxel is similar to that seen in other CALGB trials of the single agents carboplatin, trimetrexate and 5-azacytidine. Future studies of of paclitaxel (at lower doses) in combination with synergistic agents could be considered.

Original languageEnglish (US)
Article number10.5.597
Pages (from-to)597-600
Number of pages4
JournalAnnals of Oncology
Volume10
Issue number5
DOIs
StatePublished - 1999

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Keywords

  • Mesothelioma
  • Paclitaxel

Fingerprint Dive into the research topics of 'High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234'. Together they form a unique fingerprint.

Cite this